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Interleukin 6 gene promoter polymorphism is not
associated with Kawasaki disease
MH Sohn1, M-W Hur2 and DS Kim1
1Department of Pediatrics, and 2Biochemistry and Molecular Biology, Yonsei University College of Medicine, Severance Hospital,
CPO Box 8044, Seoul 120–752, Korea
We examined the IL-6 gene promoter and detected several interesting promoter polymorphisms: GGGCTG insertion at
+162 bp and G deletion at +168 bp positions (M1), A to G substitution at −594 bp (M2) of the reported IL-6 promoter
sequence. Other rare variations were also observed at several positions: −583 bp (T insertion), −507 bp (C insertion), −71
bp (T deletion), +17 bp (C insertion), and +121 bp (GC insertion). Although Kawasaki disease (KD) patients demonstrate
a drastic increase in serum interleukin-6 (IL-6) during the acute phase that parallels the duration of fever, there were no
significant differences in the nucleotide sequence between the KD patients and normal control group. By transient
transfection with IL-6 gene promoter-luciferase fusion plasmids into CV-1 cells, we tested the functional significances of
the polymorphisms. Mutations at +162 bp, +168 bp and −594 bp significantly decreased luciferase expression (P  0.05),
suggesting the promoter elements flanking the mutated nucleotides are important in transcriptional activation. Genes and
Immunity (2001) 2, 357–362.
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Introduction
Kawasaki disease (KD) is an acute febrile illness that
primarily affects infants and young children.1 The major
clinical features are fever lasting longer than 5 days, bilat-
eral conjunctival injection, enlarged cervical lymph
nodes, erythematous indurations of hands and feet,
inflammation of lips, oropharynx, and tongue, and poly-
morphous skin rashes.2
Despite well-defined clinical descriptions, its underly-
ing pathogenesis and the cause of the disease remain to
be elucidated. Many studies have suggested that immune
activation may contribute to the pathogenesis of KD.
Abnormalities of immunoregulation include increased in
activated CD4+ T cells3 and activated monocytes,4,5 and
polyclonal activation of B cells.6–8 In addition, inflamma-
tory cytokines such as tumor necrosis factor- (TNF-),9
interleukin-1 (IL-1),10 and interleukin-6 (IL-6)11,12 have
been shown to be elevated in the serum of the Kawasaki
patients during the acute phase.
IL-6 is a pleiotropic cytokine involved in the regulation
of immune response, acute phase reaction and hematopo-
iesis. IL-6 is produced by a variety of cells after various
stimulations such as infection, trauma and immunolog-
ical challenge.13 Serum IL-6 rises significantly in conjunc-
tion with fever during acute phase, and then falls to nor-
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mal in parallel with return of body temperature during
subacute phase of the KD.11 Interestingly, serum IL-6
during acute phase showed a significant correlation with
the duration of fever in the patients who were not treated
with intravenously administered gamma globulin
(IVGG).14 Thrombocytosis is frequently observed during
subacute phase of disease, which might be caused by
stimulation of IL-6 to megakaryocytes in bone marrow.
Many of the clinical and laboratory features of KD are a
reflection of a vigorous hepatic acute phase response,
mainly caused by IL-6.12
These findings may suggest that the regulation of IL-6
expression in KD patients differs from normal children,
possibly by promoter polymorphisms. In Caucasians,
two of the point mutations have been described: the G/C
element at −172 bp15 and the G/A element at −594 bp.16
In Japanese woman, the C/G substitution at −634 bp and
the G/A substitution at 4391 in 3 non-coding portion of
exon 5 were identified.17 A biallelic (G/C) single nucleo-
tide polymorphism (SNP) at −573 bp was identified in
African-Americans.18 Recently Jordanides et al19 exam-
ined three SNP at positions −594, −570, −192 in the 5
promoter region and one VNTR at the 3 region in the
human IL-6.
In relation to the disease, it was reported that the sys-
temic lupus erythematosus (SLE)-associated IL-6 XbaI
restriction alleles had duplications of AT-repeat
sequences and this variability may be related to the
aberrant IL-6 expression.20 In the sporadic Alzheimer’s
disease, an association of the C allele of the IL-6 geno-
types with delayed initial onset and reduced disease risk
was noted.21 Fishman et al22 reported that G to C
mutation at −174 bp in the IL-6 promoter of the patients
with systemic-onset juvenile chronic arthritis. The −174 C
allele showed lower IL-6 expression than the −174 G
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Figure 1 Serum interleukin-6 levels in serial samples obtained from
the Kawasaki patients during acute and subacute phases of illness
and normal controls.
Figure 2 (a) A schematic representation of the 5 flanking region of the IL-6 gene indentifying the location of mutation and transcription
factor binding sites: GRE1 and GRE2 (glucocorticoid responsive elements 1 and 2), AP-1 (activator protein-1), NRD (negative regulatory
domain), CRE (cAMP responsive element), NF-IL6 (nuclear factor of interleukin-6), NF-B (nuclear factor kappa B); (b) Regions and
sequences of mutation compared with wild-type IL-6 promoter.20
allele. IL-6 serum levels are lower in subjects with the
CC genotype compared with GC or GG subjects. These
findings suggest that the individual IL-6 genotype may
be relevant in other conditions where IL-6 levels are
increased, as in KD.
With these considerations, we investigated the IL-6
promoter polymorphism in KD patients and healthy con-
trols to explore the possibility that IL-6 gene may be
involved in the pathogenesis of KD.
Results
Serum IL-6 levels
In all 10 healthy children, serum IL-6 level was below 5
pg/ml. In contrast, the serum IL-6 level was markedly
elevated in patients with acute KD, ranging from 60.5 to
208.3 pg/ml. The mean value was 136.9 pg/ml. As
shown in Figure 1, IL-6 level in sera collected during sub-
acute phase was significantly reduced compared with
that during acute phase of KD which ranged from unde-
tectable to 72.5 pg/ml: the mean was 20.9 pg/ml.
Polymorphism of IL-6 promoter
G to C substitution polymorphism at −174 bp was not
found in KD patients and normal control. However, we
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GGGCTG insertion at +162 bp and G deletion at +168 bp
(M1), A to G substitution at −594 bp (M2) of the reported
IL-6 promoter sequence (Figure 2). The M1 and M2
mutations were seen simultaneously in seven of 10 KD
patients and also in seven of 10 normal controls. Other
rare consistent sequence variations different from the
reported promoter sequence were observed: −583 bp (T
insertion), −507 bp (C insertion), −71 bp (T deletion), +17
bp (C insertion), and +121 bp (GC insertion). There were
no significant differences between the KD patients and
normal control group.
Functional studies
We suspect that M1 and M2 mutation might have a func-
tional influence on the expression of IL-6 gene. We intro-
duced the IL-6 promoter-luciferase constructs containing
M1 and M2 polymorphism into CV-1 and HeLa cells by
transient transfection (Figure 3). In unstimulated CV-1
Figure 3 (a) A schematic representation of the plasmid containing
M1, M2 mutations used for transient transfection assays: M1 (IL-6
promoter luciferase fusion construct with mutation at +162 bp and
+168 bp), M2 (IL-6 promoter luciferase fusion construct with
mutation at −594 bp), M1+M2 (IL-6 promoter luciferase fusion con-
struct with M1 and M2 mutation), X (site of mutation identified),
+1 (transcription start site), P (direction of transcription); (b)
Luciferase activity expressed in CV-1 cells. M1 and M2 mutations
significantly decreased luciferase expression in unstimulated cells
and significantly increased luciferase expression by stimulation
with either IL-1 or LPS; (c) Luciferase activity expressed in HeLa
cells. A significant difference in reporter expression was noted only
in the double mutant (M1 and M2) construct in unstimulated cells.
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cells, the M1 construct showed 1.5-fold lower expression
than the wild-type. M2 construct showed 2.2-fold lower
expression than wild-type. The plasmid bearing M1 and
M2 mutation showed the lowest expression and 6.2-fold
lower expression than wild-type (P  0.05). Upon stimu-
lation with IL-1, expression from M1 construct increased
respectively compared with the wild-type. M2 construct
increased 1.8-fold compared with M1 construct. The plas-
mid with M1 and M2 mutations increased 3.3-fold com-
pared with wild-type (P  0.05). On stimulation with
lipopolysaccharide (LPS), expression from M1 construct
increased 1.8-fold compared with the wild-type, M2 con-
struct increased 2.4-fold compared with wild-type. The
plasmid with M1 and M2 mutations increased 5.9-fold
compared with wild-type (P  0.05). When HeLa cells
were stimulated with IL-1 or LPS, no significant increase
was noted compared to the results using CV-1 cells. Only
a significant difference was noted in the expression of IL-
6 gene between the wild-type and the plasmid with M1
and M2 mutations in the unstimulated cells (P  0.05).
Discussion
In contrast to our expectation, there was no evidence for
genetic association conferred by IL-6 promoter polymor-
phisms at the position −174 with respect to susceptibility
to KD. Interestingly, there is another report that IL-6 pro-
moter polymorphisms at −174 region is not associated
with ankylosing spondylitis,23 even though IL-6 levels
increased during this disease. This potentially suggest the
difference in post-transcriptional regulation of IL-6 gene
expression between normal group and KD patients.
And there were no significant differences in the nucleo-
tide sequences between the KD patients and normal con-
trol groups. However, we detected several interesting
promoter polymorphisms both in KD and normal con-
trols: GGGCTG insertion at +162 bp, G deletion at +168
bp positions (M1) and A to G substitution at −594 bp (M2)
of the reported IL-6 gene promoter sequence. Especially
−594 position was the same site reported as FokI poly-
morphism by Faulds et al.16 And other rare consistent
sequence variations different from the reported sequence
were also observed at several positions: −583 bp (T
insertion), −507 bp (C insertion), −71 bp (T deletion), +17
bp (C insertion), and +121 bp (GC insertion).
It is well established that the occurrence of KD may be
six times more likely in Korean children than in Cauca-
sian.24 We suggested that these interethnic variations in
the frequencies of polymorphisms might be associated
with different frequencies of KD occurrence. Potentially,
M1 and M2 polymorphisms of IL-6 promoter gene in
Korean children may contribute to frequent incidence
of KD.
By preparing IL-6 promoter-luciferase fusion con-
structs (pGL3-IL-6-wild type, −M1, −M2, −(M1+M2)) and
transient transfection assays in CV-1 and HeLa cells, we
tested the functional significances of the polymorphisms
(M1 and M2) and showed different results in each cell
type. The reasons for such difference in the CV-1 and
HeLa cells may be attributed to the different suscepti-
bility to IL-1 and LPS in different cell types. Especially
the inflammatory cytokines such as IL-6 may be more
important in the organs prone to infection, such as CV-
1 cells from kidney rather than HeLa cells from cervix.
In CV-1 cells, mutations at these positions significantly
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decreased luciferase expression. Repressive activity of
M1 is less potent than that of M2. Repressive activities of
M1 and M2 have additive activity. However, these two
mutations significantly increased luciferase expression
with the stimulation of IL-1 and LPS. After stimulation
with IL-1 and LPS, M2 shows more increased luciferase
expression than M1. And also M1 and M2 mutations
have additive activity of increased luciferase expression.
LPS has more potent stimulatory activity than IL-1, in
contrast to Fishman report20 in which IL-1 had more
potent stimulatory activity. These results suggested that
the promoter elements at which the mutations were intro-
duced are important in transcriptional activation of IL-6
gene. IL-1 and LPS potently stimulated luciferase
expression on the wild-type and mutant reporter con-
structs, suggesting that the mutations may affect the
interaction with transcriptional factors critical in the tran-
scription of IL-6. With these results, we may explain that
an increased incidence of KD in Korean children is in part
from these polymorphisms in IL-6 gene.
Computational search for transcription factors binding
site of IL-6 gene promoter shows that GCF-CS, SV40 T-
Ag and Sp-1 can bind to the wild-type M1 region (+162
bp, +168 bp). When the region is mutated into M1, three
more transcription factors (AP-2, CTCF-RS, APRT-
mouse) can potentially bind to the region. At the wild-
type M2 region (−594 bp), no transcription factor binds
to the region, but once mutated, SV40 T-Ag, CTRF-RS
and PuF-RS can potentially recognize the M2 mutated
sequence. These alterations in transcription factor bind-
ing may be important in the transcriptional regulation of
IL-6 gene. However, we do not know interactions among
these transcription factors and which mechanisms are
involved in the increase of IL-6 gene expression by IL-1
and LPS.
Table 1 Sequences of used primers
Primers used to generate PCR products for analysis of IL-6 gene
DF20 5-GGAGTCACACACTCCACCT-3
DF21 5-GTGACTGACAGCACAGCT-3
IL6 KpnI 5-GATCGGTACCGGAGTCACACACTCCACCTGGAGACGCC-3
IL6 HindIII 5-GCTAGAAGCTTGTGACTGACAGCACAGCTGGGAGCCTGC-3
Primers used for manual sequencing
MIS 5-AGAGTAAAGCTGAAGTCATGCACGAAG-3
MIR 5-CTTCGTGCATGACTTCAGCTTTACTCT-3
MS 5-ATATTTATTGGGGGTTGAGACTCTAAT-3
MR 5-CAAATGTGGGATTTTCCCATGAGTCTCAA-3
Primers used for PCR-based site-directed mutagenesis
Mut 810 Forward 5-GAGGGGTGTGTGGCCCAGGGATGCGGGGCGCCAGCAGAGGCAGGCTC-3
Mut 810 Reverse 5-GAGCCTGCCTCTGCTGCTGGCGCCCCGCATCCCTGGGCCACACACCCCTC-3
Mut 60 Forward 5-GCACGAAATTTGAGGATGGCCAGGCAGTCTAC-3
Mut 60 Reverse 5-GTAGACTGCCTGGCCATCCTCAAATTTCGTGC-3
Primers used for confirming site-directed mutagenesis
T7 promoter within pT7 5-TCTAATACGACTCACTATAGG-3
U-19 mer within pT7 5-GGTTTTCCCAGTACGCGACG-3
Materials and methods
Patients and controls
Blood samples were obtained from 10 patients (four
females) with KD, who were admitted at the Severance
Hospital, Yonsei University College of Medicine, Seoul,
Korea. All patients satisfied at least five of the six diag-
nostic criteria KD. The mean age was 2.9 years (range
from 9 months to 5 years). All patients were treated with
IVGG in addition to the high-dose aspirin therapy. Whole
bloods were collected at the acute dignostic phase, before
the initiation of any therapy. Ten normal children with-
out any medical history of KD had their blood samples
taken before undergoing elective surgical procedures.
The mean age was 3.1 years (range from 1 to 5 years).
The informed consents were obtained from the parents
of the children included in this study.
Extraction of genomic DNA
Genomic DNA was extracted from the whole blood
samples of the patients and the controls using E.Z.N.A.
Blood DNA kit (Omega Bioteck, GA, USA).
PCR
The sequences of primers are given in Table 1. Two
enzyme sites, KpnI and HindIII, were incorporated into
forward and reverse amplified primers used to amplify
the promoter region of IL-6 gene. These primers ampli-
fied promoter of 858 bp, starting upstream of the distal
putative glucocorticoid response element and finishing
adjacent to the main translation start site. The cycling
conditions were: denaturation at 94°C for 3 min, 35 cycles
of amplification (94°C 30 sec, 66°C 1 min, and 72°C 1 min)
and final 72°C, 10 min. PCR products were analyzed by
2% agarose gel electrophoresis.
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The PCR products were purified with QIAqick gel extrac-
tion kit (Qiagen, CA, USA) and sequenced with auto-
matic DNA sequencer (ALF express, Amersham Pharma-
cia, Uppsala, Sweden) using primer sets shown in
Table 1.
Cloning of PCR products
PCR products were seperated by 2% agarose gel electro-
phoresis and purified using Quiagen II gel extraction kit
(Quiagen). Purified PCR products were digested with
KpnI and HindIII and cloned into pT7-blue script
KS/KpnI·HindIII vector (Novagen, WI, USA). Then
recombinant plasmid DNA was purified using QIAprep
miniprep kit (Qiagen). Promoter sequences were determ-
ined by automatic DNA sequencer (ALF express).
Site-directed mutagenesis
Using pGL3-IL-6 promoter-luciferase as template, PCR-
based site-directed mutagenesis was performed using
Quick Change Site-Directed Mutagenesis Kit (Stratagene,
CA, USA) (Table 1). The cycling conditions were: 95°C
for 30 sec, then 18 cycles of 95°C for 30 sec, 55°C for 1
min, and 68°C for 7 min. DNA was further treated with
DpnI at 37°C for 1 h. Transformation into Epicurian Coil
XL1-Blue Supercompetent cells was performed with 1 l
of digested DNA. After mini-scale preparation of plas-
mids, mutation was confirmed by DNA sequencing using
T7 sequences primer (Table 1).
Il-6 promoter-luciferase reporter fusion plasmid
constructs
Plasmid containing mutation was digested with HindIII,
then filled-in with Klenow and dNTP, and further
digested with BamHI. Then IL-6 promoter restructing
fragment/Blunt·BamHI was cloned to pGL3 Basic
Luciferase vector/SamI·BglII.
Transient transfections
Five × 105 monkey kidney cell line CV-1 cells and human
cervix cell line HeLa cells were seeded into each well of
a six-well plate and grown to confluence in Dulbecco’s
modified Eagle’s medium (GIBCO BRL, MD, USA) sup-
plemented with 10% FCS, non-essential amino acids and
penicillin 50 U per ml/streptomycin 50 g per ml (Sigma,
MO, USA). CV-1 and HeLa cells were transfected with
0.6 g of reporter plasmid and 50 ng of pCMV--gal
which lacks a cytokine responsive promoter using Lipo-
fectamin plus transfection reagent (GIBCO BRL). After
24 h, the cells were stimulated with either 10 U/ml of IL-
1 (R & D Systems, MN, USA) or 10 g/ml of LPS (Sigma).
After incubating the cells another 24 h, the cells were har-
vested. Luciferase and -galacosidase expression were
measured using commercial assay kits (Promega, WI,
USA). Transfection was repeated three times. Transient
efficiencies and cell lysate recovery were normalized with
-galactosidase activities.
Measurement of serum IL-6
The serum samples were obtained from KD patients in
the acute phase at the time of diagnosis, before the
initiation of any therapy. Serial samples were obtained
from the patients subsequently in the subacute phase,
when the patients were afebrile. The samples were stored
at −70°C until measured. IL-6 concentration was meas-
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ured in duplicate using a commercially available ELISA
kit (R&D Systems).
Statistical methods
The concentrations of serum IL-6 between acute and sub-
acute phase of disease were compared by utilizing paired
t-test. Analysis of variance was used in comparing levels
of luciferase among the constructs. Statistical significance
was considered to be at 0.05 levels.
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